Request Demo
Last update 20 Mar 2025
GSK-3845097
Last update 20 Mar 2025
Overview
Basic Info
Drug Type TCR-T Cell therapy |
Synonyms |
Target |
Action inhibitors |
Mechanism NY-ESO-1 inhibitors(Cancer/testis antigen 1 inhibitors), TGF-β inhibitors(Transforming growth factor beta inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with GSK-3845097NCT04526509
Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, Alone or in Combination With Other Agents, in Participants With Advanced Tumors
NCT05943990
Assessment of Safety and Recommended Phase 2 Dose of Autologous T Cells Engineered With an Affinity-enhanced TCR Targeting NY ESO 1 and LAGE 1a, and Co-expressing the dnTGF-βRII (GSK3845097) in Participants With NY ESO 1 and/or LAGE 1a Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
100 Clinical Results associated with GSK-3845097
Login to view more data
100 Translational Medicine associated with GSK-3845097
Login to view more data
100 Patents (Medical) associated with GSK-3845097
Login to view more data
100 Deals associated with GSK-3845097
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 1 | Australia | 21 Dec 2020 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | Sweden | 21 Dec 2020 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | Canada | 21 Dec 2020 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | United States | 21 Dec 2020 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | Netherlands | 21 Dec 2020 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | Germany | 21 Dec 2020 | |
| Myxoid Liposarcoma | Phase 1 | Canada | 21 Dec 2020 | |
| Myxoid Liposarcoma | Phase 1 | Germany | 21 Dec 2020 | |
| Myxoid Liposarcoma | Phase 1 | Netherlands | 21 Dec 2020 | |
| Myxoid Liposarcoma | Phase 1 | Australia | 21 Dec 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free